<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735628</url>
  </required_header>
  <id_info>
    <org_study_id>19769</org_study_id>
    <nct_id>NCT03735628</nct_id>
  </id_info>
  <brief_title>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Multi-center, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the dose escalation part of this study is to determine the feasibility of&#xD;
      using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and&#xD;
      to determine the maximum tolerated dose of copanlisib in combination with nivolumab. The&#xD;
      maximum tolerated dose will then be used in Phase 2 (dose expansion) of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study was originally designed with both Phase I and Phase II part, but sponsor decided not to&#xD;
      conduct Phase 2 part due to strategic portfolio re-prioritization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Frequency of dose limiting toxicities (DLT) at each dose level associated with administration of copanlisib and nivolumab</measure>
    <time_frame>At the end of Cycle 2 of a 28-day cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response rate (ORR) as per RECIST v 1.1 (Response evaluation criteria in solid tumors, v 1.1) (by local investigator</measure>
    <time_frame>Up to 26 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Overall response rate (ORR) as per RECIST v 1.1 (by local investigator assessment)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2:Maximum drug concentration in plasma (Cmax) of copanlisib</measure>
    <time_frame>At cycle1 day15, cycle2 day15, cycle 6 day15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2:Area under the curve (AUC) of copanlisib</measure>
    <time_frame>At cycle1 day15, cycle2 day15,cycle 6 day15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Cmax for nivolumab</measure>
    <time_frame>At cycle1 day15, cycle2 day15,cycle 6 day15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Minimum plasma drug concentration (Cmin) for nivolumab</measure>
    <time_frame>At cycle1 day15, cycle2 day15,cycle 6 day15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Overall survival (OS)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Progression-free survival (PFS)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Disease control rate (DCR)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Duration of stable disease (DSD)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Time to response (TTR)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Time to progression (TTP)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2: Duration of response (DOR)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2:Number of participants with Adverse events (AE) and Serious AEs (SAE)</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2:Number of participants with clinically significantly abnormal changes in electrocardiograms (ECG) including heart rate and measures PR, QRS, QT, and QTc intervals</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and 2:Number of participants with changes in dose including interruptions, reductions and dose intensity</measure>
    <time_frame>Up to 26 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <condition>Head and Neck Squamous Cell Carcinoma (HNSCC)</condition>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Copanlisib:&#xD;
45 mg (dose level -1) or 60 mg (dose level 1) on Day 1, Day 8 and Day 15 (28 day cycle)&#xD;
Nivolumab:&#xD;
240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Copanlisib:&#xD;
Recommended phase 2 dose established in the phase 1b part on Day 1, Day 8 and Day 15 (28 day cycle)&#xD;
Nivolumab:&#xD;
240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib</intervention_name>
    <description>Copanlisib: lyophilisate for reconstitution and further dilution for infusion</description>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab: concentrate for solution for infusion</description>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with a histologically confirmed diagnosis of:&#xD;
&#xD;
        Phase 1b:&#xD;
&#xD;
          -  Advanced solid tumors where nivolumab is indicated as per the latest nivolumab&#xD;
             Prescribing Information,&#xD;
&#xD;
        Phase 2:&#xD;
&#xD;
          -  Metastatic NSCLC, progressing on or after prior pembrolizumab therapy with or without&#xD;
             chemotherapy, irrespective of PD-L1 expression Patients with EGFR or ALK genomic tumor&#xD;
             aberrations should have disease progression on FDA-approved therapy for these&#xD;
             aberrations.&#xD;
&#xD;
          -  Recurrent or metastatic HNSCC progressing on or after prior pembrolizumab therapy with&#xD;
             or without chemotherapy&#xD;
&#xD;
          -  HCC progressing after any prior therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease. Participants with vitiligo, type I&#xD;
             diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring&#xD;
             hormone replacement, psoriasis not requiring systemic treatment, or conditions not&#xD;
             expected to recur in the absence of an external trigger are permitted to enroll.&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury â‰¤ 28 days prior to first&#xD;
             administration of study intervention. Central line surgery is not considered major&#xD;
             surgery&#xD;
&#xD;
          -  Symptomatic metastatic brain or meningeal carcinomatosis or tumors unless the&#xD;
             participant is &gt; 6 months from definitive therapy (surgery or radiotherapy), has no&#xD;
             evidence of tumor growth on an imaging study and is clinically stable with respect to&#xD;
             the tumor at the start of study intervention.&#xD;
&#xD;
          -  Other malignancy within the last 5 years except for the following, which are&#xD;
             permitted:&#xD;
&#xD;
               -  curatively treated basal cell/squamous cell skin cancer,&#xD;
&#xD;
               -  carcinoma in situ of the cervix,&#xD;
&#xD;
               -  superficial transitional cell bladder carcinoma (if BCG [Bacillus&#xD;
                  Calmette-Guerin] treatment was given, there should be a minimum of 6 months&#xD;
                  between last dose and enrollment),&#xD;
&#xD;
               -  in situ ductal carcinoma of the breast after complete resection,&#xD;
&#xD;
               -  participants with localized, resected and/or low-risk prostate cancer may be&#xD;
                  eligible after discussion with the sponsor's designated medical representative&#xD;
                  and sponsor's approval.&#xD;
&#xD;
          -  Other protocol inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tower Hematology/Oncology Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211-1850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903-4900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

